Table 2.
Characteristics of interviewees.
| Interviewees (n = 143) | Patients, patient repr. and caregivers (n = 24) | Industry repr. (n = 24) | Regulators (n = 23) | HTA/payer repr. (n = 24) | Physicians (n = 24) | Academics (n = 24) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | n | % | |
| Country | ||||||||||||
| Italy (n = 24) | 4 | 17% | 4 | 17% | 4 | 17% | 4 | 17% | 4 | 17% | 4 | 17% |
| Romania (n = 23) | 4 | 17% | 4 | 17% | 3 | 13% | 4 | 17% | 4 | 17% | 4 | 17% |
| Sweden (n = 24) | 4 | 17% | 4 | 17% | 4 | 17% | 4 | 17% | 4 | 17% | 4 | 17% |
| UK (n = 24) | 4 | 17% | 4 | 17% | 4 | 17% | 4 | 17% | 4 | 17% | 4 | 17% |
| France (n = 12) | 2 | 8% | 2 | 8% | 2 | 9% | 2 | 8% | 2 | 8% | 2 | 8% |
| Germany (n = 12) | 2 | 8% | 2 | 8% | 2 | 9% | 2 | 8% | 2 | 8% | 2 | 8% |
| Netherlands (n = 12) | 2 | 8% | 2 | 8% | 2 | 9% | 2 | 8% | 2 | 8% | 2 | 8% |
| US (n = 12) | 2 | 8% | 2 | 8% | 2 | 9% | 2 | 8% | 2 | 8% | 2 | 8% |
| Disease area* | ||||||||||||
| Lung cancer | 6 | 25% | NA | NA | NA | 6 | 25% | NA | ||||
| Rheumatoid arthritis | 6 | 25% | NA | NA | NA | 6 | 25% | NA | ||||
| Muscular dystrophy | 6 | 25% | NA | NA | NA | 6 | 25% | NA | ||||
| Cardiovasc. disease | 6 | 25% | NA | NA | NA | 6 | 25% | NA | ||||
| Self-reported familiarity with PP | ||||||||||||
| Very familiar/Expert | 1 | 4% | 4 | 17% | 3 | 13% | 2 | 8% | 0 | 0% | 12 | 50% |
| Moderately familiar | 7 | 29% | 11 | 46% | 13 | 57% | 16 | 67% | 6 | 25% | 7 | 29% |
| Not familiar | 16 | 67% | 9 | 38% | 7 | 30% | 6 | 24% | 18 | 75% | 5 | 21% |
Cardiovasc., cardiovascular; NA, not applicable; PP, patient preferences; Reg., regulators; repr., representatives; HTA, Health Technology Assessment; UK, United Kingdom; US, United States; *specific disease areas w here only applicable to patients, patient representatives, caregivers, and physicians.